None of the PAOS-CBD and PAOS-PSP patients had mutations in progranulin (GRN), MAPT or C9ORF72, and we did not see any difference in TMEM106B genotype or APOE ε4 frequency across PAOS-CBD and PAOS-PSP (Table 1). This evidence concerns the gene MAPT and juxtacortical osteosarcoma.